Handelsbanken Fonder AB Grows Stock Position in Catalent, Inc. (NYSE:CTLT)

Handelsbanken Fonder AB grew its stake in Catalent, Inc. (NYSE:CTLT - Free Report) by 237.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,400 shares of the company's stock after purchasing an additional 29,844 shares during the period. Handelsbanken Fonder AB's holdings in Catalent were worth $1,905,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of CTLT. CWM LLC lifted its stake in shares of Catalent by 19.7% in the 3rd quarter. CWM LLC now owns 6,113 shares of the company's stock valued at $278,000 after purchasing an additional 1,005 shares during the last quarter. Exchange Traded Concepts LLC bought a new stake in shares of Catalent during the 3rd quarter worth approximately $31,000. Czech National Bank lifted its stake in shares of Catalent by 47.8% during the 3rd quarter. Czech National Bank now owns 31,508 shares of the company's stock worth $1,435,000 after acquiring an additional 10,189 shares during the last quarter. Asset Management One Co. Ltd. lifted its stake in shares of Catalent by 9.3% during the 3rd quarter. Asset Management One Co. Ltd. now owns 76,471 shares of the company's stock worth $3,482,000 after acquiring an additional 6,490 shares during the last quarter. Finally, Simplicity Solutions LLC bought a new stake in shares of Catalent during the 3rd quarter worth approximately $1,603,000.

Catalent Stock Up 0.2 %

CTLT stock traded up $0.12 on Friday, hitting $55.92. 2,846,393 shares of the company's stock were exchanged, compared to its average volume of 1,545,863. Catalent, Inc. has a 12-month low of $31.45 and a 12-month high of $60.20. The firm has a 50 day moving average price of $56.68 and a two-hundred day moving average price of $48.66. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48. The stock has a market cap of $10.12 billion, a P/E ratio of -8.22, a price-to-earnings-growth ratio of 6.02 and a beta of 1.20.

Catalent (NYSE:CTLT - Get Free Report) last announced its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter last year, the firm earned $0.62 earnings per share. The firm's quarterly revenue was down 10.2% compared to the same quarter last year. As a group, equities research analysts expect that Catalent, Inc. will post 0.28 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CTLT shares. UBS Group reissued a "neutral" rating and set a $63.50 price target (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Stephens reissued an "equal weight" rating and set a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. Royal Bank of Canada reissued a "sector perform" rating and set a $63.50 price target on shares of Catalent in a research note on Tuesday, February 20th. StockNews.com initiated coverage on Catalent in a research note on Saturday. They set a "sell" rating for the company. Finally, Barclays lifted their target price on Catalent from $45.00 to $47.00 and gave the company an "equal weight" rating in a research report on Thursday, January 25th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Catalent has a consensus rating of "Hold" and an average price target of $52.46.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.